

VFONAZ[®] (Voriconazole)

Patient Alert Card

Show this card to any healthcare professional involved in your treatment

- ◆ Your name:
- ◆ Doctor's name:.....
- ◆ Treatment center/Doctor phone number:
- ◆ Date VFONAZ[®] treatment started:

Please keep this card with you at all times

If you do not understand this information, please ask your doctor to explain it to you.

See the VFONAZ[®] (Voriconazole) package leaflet for more information.

If you get any side effects, talk to your doctor, pharmacist or nurse.

Saudi Food and Drug Authority
(SFDA)

call center : 19999

E-mail: npc.drug@sfd.gov.sa

Fax: 00966112057662

Or by online:

<https://ade.sfd.gov.sa>

Pharmacovigilance department in
Tabuk Pharmaceuticals:

Email:

pv.info@tabukpharmaceuticals.com

Tel.: +966114774946

Fax : +966114782686

This risk minimization activity is approved by the SFDA. For extra copies, please contact Tabuk Pharmaceuticals at +9661147749

should avoid exposure to direct sunlight during VFONAZ[®] treatment.

It is important to cover sun exposed areas of skin and use sufficient sunscreen with high sun protection factor (SPF), as an increased sensitivity of skin to the sun's UV rays can occur. There is a small chance that skin cancer could develop over time.

You should contact your doctor immediately if you experience sunburn or severe skin reaction following exposure to light or sun.

Please ensure you undergo all follow-up visits for blood tests or skin evaluations arranged by your doctor.

Please have a list of all your other medicines and medical conditions available at each visit to a healthcare professional.